A tribute to the life and career of Holbrook Kohrt
Statistical controversies in clinical research
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
Biomarkers associated with checkpoint inhibitors
CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
Clinical, pathological and genetic features of follicular lymphoma grade 3A
Oral health and risk of colorectal cancer
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes
Pragmatic randomized clinical trials
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL
Insertion of central venous catheters (CVCs)
Reply to the letter to the editor ‘Insertion of central venous catheters (CVCs)
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment†
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
Abandoning diesel because of health perspectives
Reply to the letter to the editor ‘Abandoning diesel because of health perspectives
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC)